CML
News
Novel test detects low levels of residual CML
Key clinical point: A novel test may predict which CML patients in remission can safely stop TKI therapy. Major finding: Digital PCR for BCR-ABL1...
News
New assay detects persistent CML better, team says
A new assay is more accurate than the current gold standard for detecting residual disease in patients with chronic myeloid leukemia (CML),...
News
Generic imatinib launched with savings program
Photo by Rhoda Baer Sun Pharma has announced the US launch of imatinib mesylate tablets, which are a generic version of Novartis’s Gleevec, for...
News
KIR2DL5B genotype predicts outcome in chronic phase–CML
Key clinical point: The presence of KIR2DL5B was associated with worse outcomes in patients with chronic phase–chronic myeloid leukemia treated...
News
Cardiovascular risk assessment required with use of TKIs for CML
Key clinical point: Most patients with chronic myeloid leukemia require long-term tyrosine kinase inhibitor (TKI) therapy, and cardiovascular...
Conference Coverage
Potential new alternative in CML when TKI therapy fails
ASH Annual Meeting Photo courtesy of ASH ORLANDO, FL—ABL001, an allosteric inhibitor of BCR-ABL1, has shown early evidence of single-agent...
Conference Coverage
Chemo quadruples risk for myeloid cancers
Key clinical point: This study quantifies the risks for treatment-related myeloid cancers after chemotherapy. Major finding: Chemotherapy is...
Conference Coverage
More complete cytogenetic responses at 12 months with radotinib than imatinib
Key clinical point: Radotinib was associated with significantly higher complete cytogenetic responses and major molecular responses than was...
Conference Coverage
Nilotinib safe, effective as first-line therapy for CML-CP patients age 65 and older
Key clinical point: Age did not affect molecular response or the incidence of adverse reactions to nilotinib among patients with CML-CP. Major...
Conference Coverage
Osteoarticular pain affects CML patients stopping TKI
Photo courtesy of ASH ORLANDO, FL—Cases of musculoskeletal pain have been reported after patients stop taking tyrosine kinase inhibitors (TKIs)...
News
FDA approves generic imatinib
Photo by Steven Harbour The US Food and Drug Administration (FDA) has approved the use of imatinib mesylate, a generic version of Novartis’s...